Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance resulting from the need for repeated injections. Gene th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, Szilárd, Grishanin, Ruslan, Nguyen, Aivan, Rosario, Romeo, Greengard, Judith S., Nieves, Julio, Gelfman, Claire M., Gasmi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341454/
https://www.ncbi.nlm.nih.gov/pubmed/32671137
http://dx.doi.org/10.1016/j.omtm.2020.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341454/
https://www.ncbi.nlm.nih.gov/pubmed/32671137
http://dx.doi.org/10.1016/j.omtm.2020.06.007

Ejemplares similares